Both doses administered in PD patients were followed by more than 50 % inhibition of LRRK2 and Rab10 phosphorylation in blood, and reduced bis (monoacylglycerol) phosphate in urine, which served as biomarkers of pharmacodynamic measures, and the lower dose was better tolerated. This evidence concerns the gene LRRK2 and Parkinson disease.